Evidence map›Paper›PMID 40323213›Full record

ArticleFuture oncology (London, England)2025

Nanoray-312: phase III study of NBTXR3 + radiotherapy ± cetuximab in elderly, platinum-ineligible locally advanced HNSCC.

Christophe Le Tourneau, Zoltán Takácsi-Nagy, Sandra Nuyts, Sébastien Thureau, Feng Liu, Caroline Hoffmann, Trevor G Hackman, Maria Lesnik, Anaïs Debard, Laetitia Finzi and 10 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04892173 (A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With Locally Advanced Head & Neck Squamous Cell Carcinoma), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04892173 phase3recruitingnot on this map

A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With Locally Advanced Head & Neck Squamous Cell Carcinoma

TypeinterventionalSponsorJohnson & Johnson Enterprise Innovation Inc.Ran2021 to 2028Enrolled500ConditionsCarcinoma, Squamous CellArmsJNJ-90301900 (NBTXR3), Cetuximab, Radiation Therapy
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Lanthanide Nanotheranostics in Radiotherapy.International journal of molecular sciences · 2025
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Christophe Le TourneauDepartment of Drug Development and Innovation (D3I), Institut Curie, Paris, France.ORCID 0000-0001-9772-4686
Zoltán Takácsi-NagyCenter of Radiotherapy and National Tumorbiology Laboratory, National Institute of Oncology and Department of Oncology, Semmelweis University, Budapest, Hungary.ORCID 0000-0002-3261-0271
Sandra NuytsLaboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven, Department of Radiation Oncology, Leuven Cancer Institute, University Hospitals Leuven institution, Leuven, Belgium.ORCID 0000-0002-5540-4796
Sébastien ThureauDepartment of Radiotherapy, Centre Henri Becquerel, EA4108 LITIS QuantiF, Rouen University, Rouen, France.
Feng LiuDepartment of Radiation Oncology, Hunan Cancer Hospital, Changsha, China.
Caroline HoffmannDepartment of Drug Development and Innovation (D3I), Institut Curie, Paris, France.ORCID 0000-0002-4430-3439
Trevor G HackmanDepartment of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-9330-2398
Maria LesnikDepartment of Drug Development and Innovation (D3I), Institut Curie, Paris, France.ORCID 0000-0003-1120-4327
Anaïs DebardNanobiotix, Paris, France.ORCID 0000-0002-5423-6217
Laetitia FinziNanobiotix, Paris, France.
Kiran DevisettyClinical Development, Interventional Oncology at Johnson & Johnson, New Brunswick, NJ, USA.ORCID 0000-0001-9762-6621
Omar I VivarNanobiotix, Paris, France.ORCID 0009-0000-1461-3690
Leonard A FarberNanobiotix, Paris, France.
France NguyenDepartment of Radiation Oncology, Gustave Roussy, Villejuif, France.ORCID 0000-0003-0717-7151
Xavier LiemDepartment of Radiation Oncology, Oscar Lambret Center, Lille, France.
Eteri NatelauriDepartment of Radiation Oncology, VIAN-Krystyna Kiel Oncology Center, Kutaisi, Georgia.ORCID 0000-0002-7675-009X
Amanda PsyrriDepartment of Medical Oncology, National Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.ORCID 0000-0002-4321-766X
Martin BurianDepartment Head and Neck Surgery, Ordensklinikum Linz GmbH Barmherzige Schwestern, Linz, Germany.
Jinming YuDepartment of Radiation Oncology, Shandong Oncology Hospital, Jinan, Shandong, China.
Sue S YomDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-0779-7476

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CLINICAL

trial registrationhttps://clinicaltrials.gov identifier is NCT04892173; EudraCT Number: 2021-002163-22.

Indexed as

CetuximabChemoradiotherapyHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckAgedAged, 80 and overClinical Trials, Phase III as TopicFemaleHumansMaleTreatment OutcomeCetuximabcetuximabcisplatin-ineligiblehafnium oxide nanoparticlesH&NLA-HNSCCNBTXR3radioenhancerradiotherapy

Identifiers

PMID40323213
PMCPMC12077427

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.